Vantage Consulting Group Inc increased its position in Johnson & Johnson (NYSE:JNJ – Free Report) by 14.3% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,578 shares of the company’s stock after purchasing an additional 198 shares during the period. Vantage Consulting Group Inc’s holdings in Johnson & Johnson were worth $245,000 at the end of the most recent quarter.
Other large investors also recently modified their holdings of the company. Moneta Group Investment Advisors LLC raised its position in Johnson & Johnson by 90,144.4% in the 4th quarter. Moneta Group Investment Advisors LLC now owns 54,386,720 shares of the company’s stock valued at $9,607,414,000 after buying an additional 54,326,454 shares during the last quarter. Geode Capital Management LLC raised its position in Johnson & Johnson by 0.6% in the 4th quarter. Geode Capital Management LLC now owns 47,958,583 shares of the company’s stock valued at $8,456,643,000 after buying an additional 294,671 shares during the last quarter. Morgan Stanley raised its position in Johnson & Johnson by 12.0% in the 4th quarter. Morgan Stanley now owns 42,224,521 shares of the company’s stock valued at $7,458,962,000 after buying an additional 4,521,062 shares during the last quarter. Price T Rowe Associates Inc. MD raised its position in Johnson & Johnson by 15.1% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 29,277,774 shares of the company’s stock valued at $5,171,919,000 after buying an additional 3,849,148 shares during the last quarter. Finally, Norges Bank purchased a new stake in Johnson & Johnson in the 4th quarter valued at $4,609,399,000. 67.57% of the stock is currently owned by institutional investors.
Analyst Upgrades and Downgrades
Several brokerages have recently issued reports on JNJ. TheStreet raised Johnson & Johnson from a “c+” rating to a “b+” rating in a research report on Monday. Morgan Stanley reaffirmed an “equal weight” rating and set a $187.00 target price on shares of Johnson & Johnson in a research report on Friday, July 21st. Raymond James raised their target price on Johnson & Johnson from $181.00 to $184.00 and gave the company an “outperform” rating in a research report on Monday, July 24th. StockNews.com began coverage on Johnson & Johnson in a research report on Thursday, August 17th. They set a “strong-buy” rating for the company. Finally, Credit Suisse Group raised their target price on Johnson & Johnson from $170.00 to $175.00 and gave the company a “neutral” rating in a research report on Friday, July 21st. Eight analysts have rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $171.80.
Johnson & Johnson Stock Up 0.2 %
Shares of NYSE JNJ opened at $164.89 on Friday. Johnson & Johnson has a 52 week low of $150.11 and a 52 week high of $181.04. The business has a 50-day simple moving average of $166.64 and a two-hundred day simple moving average of $161.48. The company has a quick ratio of 0.88, a current ratio of 1.12 and a debt-to-equity ratio of 0.44. The company has a market cap of $428.54 billion, a P/E ratio of 33.38, a P/E/G ratio of 2.76 and a beta of 0.54.
Johnson & Johnson (NYSE:JNJ – Get Free Report) last issued its earnings results on Thursday, July 20th. The company reported $2.80 EPS for the quarter, topping the consensus estimate of $2.62 by $0.18. Johnson & Johnson had a return on equity of 36.72% and a net margin of 13.35%. The business had revenue of $25.53 billion during the quarter, compared to the consensus estimate of $24.63 billion. During the same quarter last year, the company earned $2.59 EPS. The firm’s revenue was up 6.3% compared to the same quarter last year. Research analysts anticipate that Johnson & Johnson will post 10.75 earnings per share for the current fiscal year.
Johnson & Johnson Announces Dividend
The business also recently announced a quarterly dividend, which will be paid on Thursday, September 7th. Shareholders of record on Monday, August 28th will be paid a $1.19 dividend. The ex-dividend date of this dividend is Friday, August 25th. This represents a $4.76 annualized dividend and a yield of 2.89%. Johnson & Johnson’s dividend payout ratio is currently 96.36%.
Insiders Place Their Bets
In other news, EVP Kathryn E. Wengel sold 12,465 shares of Johnson & Johnson stock in a transaction dated Monday, June 12th. The stock was sold at an average price of $160.00, for a total transaction of $1,994,400.00. Following the completion of the sale, the executive vice president now owns 65,934 shares in the company, valued at approximately $10,549,440. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other news, EVP Kathryn E. Wengel sold 12,465 shares of Johnson & Johnson stock in a transaction dated Monday, June 12th. The stock was sold at an average price of $160.00, for a total transaction of $1,994,400.00. Following the completion of the sale, the executive vice president now owns 65,934 shares in the company, valued at approximately $10,549,440. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, VP Peter Fasolo sold 20,000 shares of Johnson & Johnson stock in a transaction dated Tuesday, July 25th. The shares were sold at an average price of $170.32, for a total value of $3,406,400.00. Following the sale, the vice president now owns 102,696 shares of the company’s stock, valued at approximately $17,491,182.72. The disclosure for this sale can be found here. Insiders sold a total of 47,163 shares of company stock worth $7,928,856 in the last quarter. 0.20% of the stock is owned by company insiders.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.
Featured Articles
- Five stocks we like better than Johnson & Johnson
- How to Invest and Trade Chinese Stocks
- Can These 2 Industrial Titans Extend Double-Digit YTD Growth?
- 3 Fintech Stocks With Good 2021 Prospects
- How to Profit from These 3 Membership Club Stocks’ Strengths
- Most Active Stocks: Dollar Volume vs Share Volume
- 5 Best High-Yield Dividend Stocks for Any Economic Climate
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
